Work

O-6 Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib in second-line non-small cell lung cancer (NSCLC) — preliminary results

Year: 2003

Type: article

Source: Lung Cancer

DOI: 10.1016/s0169-5002(03)91664-3

Authors: Rogerio Lilenbaum, Philip Bonomi, Mark Anthony Socinski

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2080785767

FWCI: 0.284

Cites:

Cited by: 1

Related to: 10